← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Agile Sciences, Inc.
Raleigh, NC
$10,925,556
Total funding
13
Grants
Funding over time
peak $3.8M · FY2010–18$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$10,925,556 · 13
By mechanism
R44$3,735,850 · 3
N01$2,745,321 · 1
R43$1,622,819 · 4
R42$1,499,094 · 1
R41$1,322,472 · 4
Investigators at Agile Sciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,689,686
N01 · FY2015 · AI
Development of novel anti-biofilm compounds for treating chronic wounds$832,651
R44 · FY2016 · AI
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p$826,326
R42 · FY2015 · AI
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p$672,768
R42 · FY2014 · AI
Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections$641,088
R44 · FY2015 · AI
Development of novel anti-biofilm compounds for treating chronic wounds$635,323
R44 · FY2015 · AI
Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections$596,514
R44 · FY2016 · AI
Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates$530,688
R44 · FY2012 · DE
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$499,839
N01 · FY2018 · AI
Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates$499,586
R44 · FY2013 · DE
Anti-biofilm agents for treating pulmonary infection in Cystic Fibrosis patients$428,163
R41 · FY2011 · AI
Development of Novel Anti-Biofilm Compounds for Treating Chronic Wounds$300,000
R41 · FY2011 · AI
Evaluation of a new class of molecules for treating MRSA infective endocarditis$300,000
R41 · FY2013 · AI
Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria$294,309
R41 · FY2016 · AI
Prevention of Bacterial Biofilms on CSF Shunts through the Incorporation of Novel$285,619
R43 · FY2010 · NS
Prevention of Bacterial Biofilms on CSF Shunts through the Incorporation of Novel$284,496
R43 · FY2011 · NS
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$282,822
N01 · FY2017 · AI
Development of Small Molecules to Combat Bacterial Biofilms$275,956
R43 · FY2011 · GM
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$272,974
N01 · FY2016 · AI
Development of Small Molecules to Combat Bacterial Biofilms$267,690
R43 · FY2012 · GM